SILVERARC CAPITAL MANAGEMENT, LLC - Q1 2023 holdings

$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .

 Value Shares↓ Weighting
CUE  Cue Biopharma Incequities$1,093,412
+25.3%
306,2780.0%0.45%
+80.4%
 Fresh Tracks Therapeutics Incequities$6,600
-56.0%
10,0000.0%0.00%
-25.0%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • SilverArc Capital, LLC #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTRA-CELLULAR THERAPIES INC12Q3 20237.8%
IMMUNOGEN INC12Q3 20238.3%
Morphic Holding Inc12Q3 20234.5%
UNUM THERAPEUTICS INC12Q3 20233.2%
INSMED INC12Q3 20233.5%
UNITED THERAPEUTICS CORP DEL12Q3 20232.2%
MERUS N V11Q3 20235.1%
VERACYTE INC11Q3 20234.9%
EVOGENE LTD11Q3 20231.6%
COMPUGEN LTD11Q3 20231.1%

View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
SILVERARC CAPITAL MANAGEMENT, LLC Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Benitec Biopharma Inc.Sold outFebruary 08, 202300.0%
DELCATH SYSTEMS, INC.Sold outFebruary 08, 202200.0%

View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G2024-02-14
SC 13G2024-02-14
SC 13G2024-02-14
13F-HR2023-11-13
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
SC 13G/A2023-02-08
13F-HR2022-10-28

View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.

Compare quarters

Export SILVERARC CAPITAL MANAGEMENT, LLC's holdings